378 related articles for article (PubMed ID: 29478255)
1. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
Trautmann ME; Vora J
Diabet Med; 2018 Jun; 35(6):694-706. PubMed ID: 29478255
[TBL] [Abstract][Full Text] [Related]
2. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
Wilding JP; Bain SC
Diabet Med; 2016 Jul; 33(7):864-76. PubMed ID: 26525806
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy.
Kitazawa T; Yokoyama K; Kubota K
J Diabetes Investig; 2016 May; 7(3):381-5. PubMed ID: 27330725
[TBL] [Abstract][Full Text] [Related]
4. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
5. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
7. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Blumer I; Pettus JH; Santos Cavaiola T
Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
[TBL] [Abstract][Full Text] [Related]
8. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Banerji MA; Baron MA; Gao L; Blonde L
Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
[TBL] [Abstract][Full Text] [Related]
9. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
10. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.
Balena R; Hensley IE; Miller S; Barnett AH
Diabetes Obes Metab; 2013 Jun; 15(6):485-502. PubMed ID: 23061470
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
13. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.
Leiter LA; Gross JL; Chow F; Miller D; Johnson S; Ahrén B;
J Diabetes Complications; 2017 Aug; 31(8):1283-1285. PubMed ID: 28587789
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
Perreault L; Rodbard H; Valentine V; Johnson E
Adv Ther; 2019 Feb; 36(2):265-277. PubMed ID: 30610613
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA; Meier JJ; Nauck MA
Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
[TBL] [Abstract][Full Text] [Related]
17. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
Darmon P; Raccah D
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
[TBL] [Abstract][Full Text] [Related]
18. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
Shaefer CF; Anderson J
Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
[TBL] [Abstract][Full Text] [Related]
19. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Esposito K; Giugliano D
Diabetes Obes Metab; 2018 Sep; 20(9):2309-2313. PubMed ID: 29732679
[TBL] [Abstract][Full Text] [Related]
20. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
Albèr A; Brønden A; Knop FK
Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
